Adventrx Pharmac. Heisses Eisen ?

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=45517116  

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=45517096

http://stockcharts.com/c-sc/...amp;dy=0&i=p30829528559&r=5947  

By Tim Hanson and Brian Richards
January 14, 2010 | Comments (6)

Recs
8

Email
 Share
Print
Penny stocks have huge potential -- that's their blessing and their curse.

The potential rewards are enormous. In fact, pennies have been the best performers lately. Over the past 30 days, ADVENTRX Pharmaceuticals (AMEX: ANX), Adeona Pharmaceuticals (AMEX: AEN), and Petroflow Energy (AMEX: PED) are all up more than 110%.

Those quick doubles look like easy gains, considering that Apache (NYSE: APA) and ITT Educational (NYSE: ESI) would need to add $106 and $101, respectively, to their share prices to do the same.

Everybody loves pennies
It's the potential of quick gains in "cheap" stocks that keeps investors coming back. We recently typed "penny stocks" into Google, and the search engine spat out more than 10 million hits. We did the same for more time-tested terms such as "blue-chip stocks" and "dividend stocks" and got just over 1 million and 4 million hits, respectively.

Sure, we expected a discrepancy, but the size of the gap was startling. It became even more interesting when we broke down those hits with Google Trends. According to Trends, penny stocks are particularly alluring to investors in Tampa, Miami, and Orlando -- the locales where the term is most often searched.

We hope the folks Googling "penny stocks" down there aren't retirees trying to cope with this crazy, crazy market.

This stock is set to take off! Or not.
According to the Securities and Exchange Commission, the term "penny stock" generally refers to low-priced (below $5), speculative securities of very small companies. To quote the SEC: "Investors in penny stocks should be prepared for the possibility that they may lose their whole investment." (It's worth noting that the emphasis in that last sentence is in the original.)

Pay attention to the SEC's entire definition, not just the stock price. Going solely on price would wrongly categorize billion-dollar companies such as Huntington Bancshares (Nasdaq: HBAN) or Chimera Investment (NYSE: CIM) as penny stocks.

Regardless, the SEC is spot-on when it says that true penny stocks are among the surest ways to lose money in the stock market.

Well, then, why do we love penny stocks?
We love penny stocks because they're fascinating. The world of pennies is inhabited by hardworking average Joes and Janes hoping to strike it rich, as well as by pumpers and dumpers, hypesters, and scammers. In pennies, the logic and reason that applies in the rest of daily life is replaced by zeal and prayer.

However, we don't love them enough to actually buy them. Yes, they have big potential, but their daily gyrations are unpredictable -- the stock-price movements have next to nothing to do with the underlying company the stock represents. In fact, trading in pennies is highly illiquid, and prices are often manipulated by forces not at all related to the business.

The dangers of incredible promises
If you're buying stocks without paying attention to the businesses you're buying, then you might as well be buying a lottery ticket. Or, to use another analogy, you might as well buy up every baseball card of a benchwarmer on the Akron Aeros Class AA baseball team and hope that he someday rises up, fulfills his potential, and becomes an all-star for the big-league Cleveland Indians.

There's a better way
Before you start saying the rest of the stock market is boring -- though you're probably not saying that any longer -- let us introduce you to some underfollowed small caps. They're nothing like penny stocks, yet they still offer some of the best returns on the market. Unlike penny stocks, promising small caps:

File reliable financial statements.
Are transparent.
Have conference calls that individual investors can listen to.
Don't simply hype their stock in press releases.
That's a starting point. There are more -- and more important -- criteria to help you find great small-cap companies. Our team at Motley Fool Hidden Gems, for instance, looks for a balance sheet with lots of cash and no debt, and a tenured CEO (or founder, if possible) who holds a substantial ownership stake in the business. In other words, we're looking for big returns with good old-fashioned bottom-up analysis.

You can view the 50-plus small caps our team has already found with a free 30-day trial. There's no obligation to subscribe, and we particularly recommend it for the penny-stock-o-philes reading in Florida. You know who you are.

Already a Hidden Gems member? Log in at the top of this page.

This article was originally published July 27, 2006. It has been updated.

Tim Hanson and Brian Richards disagree about whether the U.S. Treasury should do away with the penny ... but the Treasury is probably busy with other issues right now. Neither owns shares of any company mentioned. Google is a Motley Fool Rule Breakers recommendation. The Fool's disclosure policy is finger-lickin' good.

Read/Post Comments (6) | Recommend This Article (8)

Email Print Feedback Digg Delicious RSS
We Are Due for a Pullback!

Stocks have made an epic run but it won't last. "The economy isn't strong enough" to support a new bull market reports The Wall Street Journal. We are overdue for a big pullback.

You have a choice: Stay the course and suffer big losses or go on the offense! The Motley Fool's top options and ETF strategist (with a 93% win rate) has created a game plan for making money with stocks you already own when the market drops again. Discover one easy tactic you can use immediately in a free report: "Options 401: How to protect your gains in an uncertain market."

Click here for instant access to your FREE report.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the  Report this Comment icon found on every comment.

Report this Comment On January 14, 2010, at 3:12 PM, nwaldman89 wrote:
you are totally right. really cheap penny stocks generally fluctuate based on traders moods that day, and are not 100%correlated to the businesses that they represent.

Gambling is what you compare it to. But the odds are much better, especially once you get a good feel for the stock. If you have a large enough arsenal of penny stocks to choose from and you watch them all fairly closely it is easy to see when to buy them and when to sell them. I have made just over 30 trades since december with stocks like ANX PED MDU:ca OXGN ETRM and more and i have only lost on a few occasions.

It is hard to compare them to gambling, unless you want to say that the whole market is a gamble.

Report this Comment On January 14, 2010, at 3:23 PM, nwaldman89 wrote:
I dont think buying penny stocks is the same as a Gamble. You watch them, you see the range that they trade in and you buy low sell high. Very simple. And sometimes you get lucky! for example i was repetatively buying ANX at 9 or 10 cents and selling at 11,(sometimes twice a day) and then we all know what happened, and now im a happy camper! but i dont think it is fair to say that trading penny stocks is a form of gambling if trading regular stocks is not. It is a skill, not just luck.Although It is a different game then larger scale stocks.

Penny Stock Winners Should Get Respect!!

Report this Comment On January 14, 2010, at 3:48 PM, bittymack wrote:
ANX will be $2.00 before you know it. Carl Icahn bought millions and they are likely being bought out:

http://newsblaze.com/story/20100110141726trho.nb/localnews/t...

Report this Comment On January 14, 2010, at 5:03 PM, mouseaggie wrote:
NVLT is another great penny stock story:

http://finance.yahoo.com/news/Novelos-Therapeutics-NVLTOB-iw...

Very likely could double from here before Phase III results come out for Nov-002, and then if successful - $8+

Report this Comment On January 14, 2010, at 7:26 PM, pleazu69 wrote:
I agree with you on ANX $2 is an easy target to hit.

Did you see that conference?

There is nothing but good thing ahead for them.

They rose from the ashes like a phoenix. Lol

ANX-530 is going to take a big part of the market

Report this Comment On January 14, 2010, at 8:12 PM, nwaldman89 wrote:
so if there is a takeover what will happen to my shares of ANX. Do they just become a different ratio of shares of the company who buys them out?


http://www.fool.com/investing/small-cap/2010/01/...-penny-stocks.aspx  

 

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=45527083  

diese kurve hatten wir schon mal keine angst leute geht demnächst wieder rauf ja nicht im minus verkaufen das bereut man zu 95%!!
lg  

 

Sollte man verknacken...immer das gleiche...meint ihr er hat sich heute eingedeckt ????
Mal der SEC schreiben dass sie seine Depots und seines Busenfreundes Cramer anschauen ? :-)
Gap ist jetzt zu, ich hab ehrlichgesagt nicht gedacht dass dies passiert, abe alle Idioten verkaufen wenn AF basht und ärgern sich wenn sie dann hinterherchasen wenns wieder up geht...

Long&Strong hier..das gebashe hat Gründe...und ich denke AF ist sowieso von Hedgefunds fürs bashen bezahlt..  

Adventrx Returns From The Brink

http://www.sandiego.com/business/adventrx-returns-from-the-brink

San Diego Business
Adventrx Returns From The Brink
San Diego biotech was close to bankruptcy; now thriving
By Eilene Zimmerman
Posted on Sat, Jan 16th, 2010
Last updated Fri, Jan 15th, 2010

Last June, things were looking pretty grim for Mira Mesa-based biotech company Adventrx (AMEX: ANX). The company was down to just two full-time employees, both executives, after its leading drug candidate failed during clinical trials. In the words of principal executive officer Brian Culley, “We were teetering on the edge of bankruptcy.” Fortunately for Culley, the company never went over.




Adventrx exec Brian Culley.

Courtesy photo


Earlier this month, Adventrx submitted a new drug application, or NDA, to the Food and Drug Administration for its anti-cancer drug, ANX-530. It's a reformulated version of a widely used chemotherapy drug known as Vinorelbine, which causes pain and inflammation about 30 percent of the time at the site of injection into a patient’s arm. ANX-530 has the same amount of the drug that is in Vinorelbine, but it does not irritate the vein.

Adventrx’s turnaround began this summer when three small private financing rounds raised about $3.5 million. At the time, Culley said the question was whether or not to use the money to manage through an orderly wind-down of the company or invest it in manufacturing. He and his partner decided to take a risk and invest it in manufacturing the 530 drug.

“We knew the compound itself was very good and could be developed, but the problems we had were in commercial scale manufacturing of the drug, and those hurdles needed to be overcome in order to file a new drug application,” says Culley.

It was a big risk because there was only enough money to do the manufacturing, but not any preliminary testing.

“We had to fly a little blindly, but we had tremendous confidence in our manufacturer, BSP Pharmaceuticals in Italy," says Culley. "We told them, ‘We have one chance to do this right. Can you do it?’ And they did, they nailed it.”

With the manufacturing challenges overcome, the company had the information it needed to file an NDA with the FDA. And that led to another round of private equity financing in October, which raised $11 million. That cash will fund the company through the submission and review of their NDA, which typically takes about 10 months, says Culley.

Adventrx still has two full-time employees (in addition to Culley, there is the company’s principal financial officer), but now it also has about 40 contractors. Its next drug is ANX-514, a detergent-free formulation of another widely used chemotherapy drug, Taxotere.

“We will be investing in 514 now to get that to the NDA stage as quickly as possible,” says Culley.

Business Sector Biotechnology  
URL http://www.adventrx.com/  


Eilene Zimmerman About the author: Eilene Zimmerman is a journalist based in San Diego who writes about a variety of topics, including business, social and political issues and family life. Her work has been published in national magazines and newspapers including The New York Times, The San Francisco Chronicle, The Christian Science Monitor, FORTUNE Small Business, CNNMoney.com, CBS MoneyWatch.com, Wired, Harper’s, Salon.com, Slate.com, Psychology Today and others. She blogs at www.trueslant.com.

More by this author  

Wegen Tradingstrategie....

Also da ich schon seit 0.20€ dabei war wäre die Tradingstrategie gewesen bei 0.50$ die hälfte vom Tisch zu nehmen und am Freitag wieder reinzuschmeissen.
Anstattdessen habe ich nur 5k shares verkauft bei 0.45$ und habe zu früh am Donnerstag wieder nachgekauft und zwar MEHR als vorher weil ich glaube dass wir hier eine SNSS bzw CYCC artigen Move sehen werden.
Nichts desdo trotz bin ich noch 4% im plus und habe jetzt fast doppelt soviel Geld drin. :-)

Ich hoffe dass AF jetzt nichts mehr schreibt, meiner Meinung nach ist das ein voll(&§%/$%§" der Überhaupt keine Ahnung hat...zumindest hat er das zu oft schon bewiesen...genauso wie sein busenfreund cramer (der hat ja auch gesagt kein RINO kaufen bei 10$ und dann gings bis 35$ LOOOL )

Es gibt noch einige andere Beispiele wo diese zwei Schmocks falsch lagen mit ihren Aussagen...aber ihr wist ja warum die beiden das tun ....erst bashen dann das Depot vollhämmern...????

---------------------
Posted by: _bbb_    Date: Saturday, January 16, 2010 2:49:30 PM  
In reply to: Funstick who wrote msg# 5330  Post # of 5338      

He is just a "biostock" copy of his other b**bbuddy s"crammer" who told somebody "NEVER buy" RINO when it was around 10$.. RINO went to 35$...lmao !
I feel save owning ANX, while he talks bad about it and the bashercrew at yanoo do naysay all day, even on the weekend without any facts to back it up.
I watched the presentation and am looking forward to the next one..our CEO seems to be very professional in contrary to that AF guy hired to talk stocks down with false misleading arguments. IMO

GO ANX !  

ANX: Technical Analysis Video [01.16.10]

A new 52-week high was succeeded by a retracement in the market. Now the price will need to find support at a level where the ‘bulls’ will once again overwhelm the ‘bears’. Analysis, in video format, follows.

Link to Video: http://timelesswealth.net/ta/anx1.html  

Posted by: Ecomike    Date: Sunday, January 17, 2010 12:41:05 AM  
In reply to: cramerfool who wrote msg# 5308  Post # of 5358      

It had strong support at the .31 price late Friday, which is an important fib number for the stock, and is now strong support, which is .07/share higher than the last low, and the last high hit the last upper resistance at .52, which is the next target to take out and try to turn into support I think, on the way to dollar land. I added more Friday at .34 after the first hard bounce off .32, as I thought it might not retest .31 before going back into the .4x range.

If we open down Tuesday, and take an early plunge below .31, I would suggest buying before it takes off again and heads back to .4x range. I expect it take out .52 next week. Also there are 2 huge gaps left overhead between .43 and .45, and between .39 and .35/share that need to be filled. And the last fib above is at .36/share!!!

I think the volatility and volume is due to huge numbers of day traders joining the long buyers at the dips. The good news is the dips are higher lows!!!!  

ADVENTRX Pharmaceuticals, Inc. and the 505(b)(2) New Drug Application (NDA) for ANX-530
January 17, 2010 by tim · Leave a Comment

There has certainly been a lot of attention paid to ADVENTRX Pharmaceuticals over the past few days so it comes as no surprise that we have had a lot of questions concerning this company’s use of a 505(b)(2) New Drug Application (NDA) for ANX-530. This NDA is different from a full NDA (the usual for a new drug) and different from an ANDA (which is used for generic drugs). The FDA defines a 505(b)(2) application as: “…one for which one or more of the investigations relied upon by the applicant for approval were not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the investigations were conducted”. It basically allows a company (like ADVENTRX) to ask the FDA for approval of its proprietary formulation of vinorelbine (ANX-530 – vinorelbine emulsion) based partly on safety and effectiveness data generated in the approval of a reference drug, which in this case is Navelbine® (vinorelbine). In its January 10, 2010 press release ADVENTRX states that it is seeking approval for the same indications as Navelbine® including non-small cell lung cancer. The company states that the 505(b)(2) NDA submission includes data from one clinical bioequivalence study designed to assess the pharmacokinetic equivalence of ANX-530 and Navelbine®, the reference drug. As such, the position of ADVENTRX would be that the data required by the FDA for approval can be adequately obtained through a small clinical trial (30 patients or so) relatively quickly and inexpensively compared to the phase I, phase II and phase III clinical trials required to support a full NDA. ADVENTRX believes that by delivering intravenous vinorelbine as an emulsion, ANX-530 can reduce the incidence and severity of vein irritation that may be associated with the administration of this chemotherapeutic agent.

Filed under Drug, Medicine, Respiratory · Tagged with 505(b)(2) NDA, ADVENTRX Pharmaceuticals, ANX-530, Navelbine, NDA, New Drug Application, Non Small Cell Lung Cancer, vinorelbine

Speak Your Mind
Tell us what you're thinking...
and oh, if you want a pic to show with your comment, go get a gravatar!
Click here to cancel reply.
You must be logged in to post a comment.
.

http://www.biohorizon.com/2010/01/...rug-application-nda-for-anx-530/  

Da kein Handel in Übersee stattfindet, wird heute nicht viel passieren....  

Startlöcher ?

Lest mal die Kommentare vom street.com Artikel...hm.. :-)

 

 

was heißt das  

auf w.o. ist ein guter bericht.  

http://www.bignews.biz/...5093&keys=ANX-CBAI-pharmaceutical-stock  

auf der anderen Seite des Teiches, spielen ja heute wieder mit....  

Scheint hoch zugehen!!!  

 

 

wenn man den sell-off im Gesamtmarkt mal betrachtet.
Einzigster Wert der an der AMEX leicht grün ist unter den top nach Volumina.

Heute war ein durchwachsender Tag...Überall nicht so rosig...  

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=45710899

Viel Glück uns hier ! :-)